Compliance with post-operative adjuvant chemotherapy in non-small cell lung cancer

An analysis of National Cancer Institute of Canada and intergroup trial JBR.10 and a review of the literature

Naveed Alam, Frances A. Shepherd, Timothy Winton, Barbara Graham, David Johnson, Robert B Livingston, James Rigas, Marlo Whitehead, Keyue Ding, Lesley Seymour

Research output: Contribution to journalArticle

110 Citations (Scopus)

Abstract

Resected non-small cell lung cancer (NSCLC) has 5-years survival rates of 30-70%. The role of adjuvant chemotherapy remains unclear with poor compliance reported in most trials. The compliance with adjuvant chemotherapy (ACT) for stage IB and II NSCLC was analyzed using data from a North American multi-centre phase III study (accrual 1994-2001) that compared adjuvant chemotherapy to observation. Planned chemotherapy consisted of cisplatin (CIS) 50 mg/m 2 days 1, 8 and vinorelbine (VIN) 25 mg/m2 days 1, 8, 15, 22 for four cycles; the VIN dose had been reduced from 30 mg/m2 after an initial cohort of patients experienced unacceptable toxicity. Four hundred and twenty-four patients were randomized after the amendment, 215 to the chemotherapy arm. Median age was 60 years, 64% were male and 84% had stage II disease. Thirty-seven patients completed one cycle, 14 completed two, 20 completed three and 108 patients completed all four cycles. Ten patients received no therapy. Multivariate analysis demonstrated statistically significant differences in compliance with extent of surgery, gender and age. Patients randomized in Canada were more likely to fail to complete chemotherapy due to refusal of therapy than their American counterparts. Patients who had pneumonectomies were more likely to discontinue therapy due to toxicity than those who had lesser resections. Extent of surgery may play a role in both the compliance and toxicity of ACT. Differences between nations in the perception of the risks and benefits of adjuvant chemotherapy regimens, both between physicians and patients, should be investigated further.

Original languageEnglish (US)
Pages (from-to)385-394
Number of pages10
JournalLung Cancer
Volume47
Issue number3
DOIs
StatePublished - Mar 2005
Externally publishedYes

Fingerprint

National Cancer Institute (U.S.)
Adjuvant Chemotherapy
Non-Small Cell Lung Carcinoma
Canada
Drug Therapy
Pneumonectomy
Cisplatin
Compliance
Therapeutics
Multivariate Analysis
Survival Rate
Observation
Physicians

Keywords

  • Adjuvant chemotherapy
  • Non-small cell lung cancer
  • Treatment compliance

ASJC Scopus subject areas

  • Oncology
  • Pulmonary and Respiratory Medicine
  • Cancer Research

Cite this

Compliance with post-operative adjuvant chemotherapy in non-small cell lung cancer : An analysis of National Cancer Institute of Canada and intergroup trial JBR.10 and a review of the literature. / Alam, Naveed; Shepherd, Frances A.; Winton, Timothy; Graham, Barbara; Johnson, David; Livingston, Robert B; Rigas, James; Whitehead, Marlo; Ding, Keyue; Seymour, Lesley.

In: Lung Cancer, Vol. 47, No. 3, 03.2005, p. 385-394.

Research output: Contribution to journalArticle

Alam, Naveed ; Shepherd, Frances A. ; Winton, Timothy ; Graham, Barbara ; Johnson, David ; Livingston, Robert B ; Rigas, James ; Whitehead, Marlo ; Ding, Keyue ; Seymour, Lesley. / Compliance with post-operative adjuvant chemotherapy in non-small cell lung cancer : An analysis of National Cancer Institute of Canada and intergroup trial JBR.10 and a review of the literature. In: Lung Cancer. 2005 ; Vol. 47, No. 3. pp. 385-394.
@article{9c0bf7a23631445984ea865de9ce2706,
title = "Compliance with post-operative adjuvant chemotherapy in non-small cell lung cancer: An analysis of National Cancer Institute of Canada and intergroup trial JBR.10 and a review of the literature",
abstract = "Resected non-small cell lung cancer (NSCLC) has 5-years survival rates of 30-70{\%}. The role of adjuvant chemotherapy remains unclear with poor compliance reported in most trials. The compliance with adjuvant chemotherapy (ACT) for stage IB and II NSCLC was analyzed using data from a North American multi-centre phase III study (accrual 1994-2001) that compared adjuvant chemotherapy to observation. Planned chemotherapy consisted of cisplatin (CIS) 50 mg/m 2 days 1, 8 and vinorelbine (VIN) 25 mg/m2 days 1, 8, 15, 22 for four cycles; the VIN dose had been reduced from 30 mg/m2 after an initial cohort of patients experienced unacceptable toxicity. Four hundred and twenty-four patients were randomized after the amendment, 215 to the chemotherapy arm. Median age was 60 years, 64{\%} were male and 84{\%} had stage II disease. Thirty-seven patients completed one cycle, 14 completed two, 20 completed three and 108 patients completed all four cycles. Ten patients received no therapy. Multivariate analysis demonstrated statistically significant differences in compliance with extent of surgery, gender and age. Patients randomized in Canada were more likely to fail to complete chemotherapy due to refusal of therapy than their American counterparts. Patients who had pneumonectomies were more likely to discontinue therapy due to toxicity than those who had lesser resections. Extent of surgery may play a role in both the compliance and toxicity of ACT. Differences between nations in the perception of the risks and benefits of adjuvant chemotherapy regimens, both between physicians and patients, should be investigated further.",
keywords = "Adjuvant chemotherapy, Non-small cell lung cancer, Treatment compliance",
author = "Naveed Alam and Shepherd, {Frances A.} and Timothy Winton and Barbara Graham and David Johnson and Livingston, {Robert B} and James Rigas and Marlo Whitehead and Keyue Ding and Lesley Seymour",
year = "2005",
month = "3",
doi = "10.1016/j.lungcan.2004.08.016",
language = "English (US)",
volume = "47",
pages = "385--394",
journal = "Lung Cancer",
issn = "0169-5002",
publisher = "Elsevier Ireland Ltd",
number = "3",

}

TY - JOUR

T1 - Compliance with post-operative adjuvant chemotherapy in non-small cell lung cancer

T2 - An analysis of National Cancer Institute of Canada and intergroup trial JBR.10 and a review of the literature

AU - Alam, Naveed

AU - Shepherd, Frances A.

AU - Winton, Timothy

AU - Graham, Barbara

AU - Johnson, David

AU - Livingston, Robert B

AU - Rigas, James

AU - Whitehead, Marlo

AU - Ding, Keyue

AU - Seymour, Lesley

PY - 2005/3

Y1 - 2005/3

N2 - Resected non-small cell lung cancer (NSCLC) has 5-years survival rates of 30-70%. The role of adjuvant chemotherapy remains unclear with poor compliance reported in most trials. The compliance with adjuvant chemotherapy (ACT) for stage IB and II NSCLC was analyzed using data from a North American multi-centre phase III study (accrual 1994-2001) that compared adjuvant chemotherapy to observation. Planned chemotherapy consisted of cisplatin (CIS) 50 mg/m 2 days 1, 8 and vinorelbine (VIN) 25 mg/m2 days 1, 8, 15, 22 for four cycles; the VIN dose had been reduced from 30 mg/m2 after an initial cohort of patients experienced unacceptable toxicity. Four hundred and twenty-four patients were randomized after the amendment, 215 to the chemotherapy arm. Median age was 60 years, 64% were male and 84% had stage II disease. Thirty-seven patients completed one cycle, 14 completed two, 20 completed three and 108 patients completed all four cycles. Ten patients received no therapy. Multivariate analysis demonstrated statistically significant differences in compliance with extent of surgery, gender and age. Patients randomized in Canada were more likely to fail to complete chemotherapy due to refusal of therapy than their American counterparts. Patients who had pneumonectomies were more likely to discontinue therapy due to toxicity than those who had lesser resections. Extent of surgery may play a role in both the compliance and toxicity of ACT. Differences between nations in the perception of the risks and benefits of adjuvant chemotherapy regimens, both between physicians and patients, should be investigated further.

AB - Resected non-small cell lung cancer (NSCLC) has 5-years survival rates of 30-70%. The role of adjuvant chemotherapy remains unclear with poor compliance reported in most trials. The compliance with adjuvant chemotherapy (ACT) for stage IB and II NSCLC was analyzed using data from a North American multi-centre phase III study (accrual 1994-2001) that compared adjuvant chemotherapy to observation. Planned chemotherapy consisted of cisplatin (CIS) 50 mg/m 2 days 1, 8 and vinorelbine (VIN) 25 mg/m2 days 1, 8, 15, 22 for four cycles; the VIN dose had been reduced from 30 mg/m2 after an initial cohort of patients experienced unacceptable toxicity. Four hundred and twenty-four patients were randomized after the amendment, 215 to the chemotherapy arm. Median age was 60 years, 64% were male and 84% had stage II disease. Thirty-seven patients completed one cycle, 14 completed two, 20 completed three and 108 patients completed all four cycles. Ten patients received no therapy. Multivariate analysis demonstrated statistically significant differences in compliance with extent of surgery, gender and age. Patients randomized in Canada were more likely to fail to complete chemotherapy due to refusal of therapy than their American counterparts. Patients who had pneumonectomies were more likely to discontinue therapy due to toxicity than those who had lesser resections. Extent of surgery may play a role in both the compliance and toxicity of ACT. Differences between nations in the perception of the risks and benefits of adjuvant chemotherapy regimens, both between physicians and patients, should be investigated further.

KW - Adjuvant chemotherapy

KW - Non-small cell lung cancer

KW - Treatment compliance

UR - http://www.scopus.com/inward/record.url?scp=13844276400&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=13844276400&partnerID=8YFLogxK

U2 - 10.1016/j.lungcan.2004.08.016

DO - 10.1016/j.lungcan.2004.08.016

M3 - Article

VL - 47

SP - 385

EP - 394

JO - Lung Cancer

JF - Lung Cancer

SN - 0169-5002

IS - 3

ER -